General MedicationsORALStandard
AQNEURSA
LEVACETYLLEUCINE
Standard Dose
1GM/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview AQNEURSA is listed in Drugs@FDA under application 219132 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient LEVACETYLLEUCINE Form and strength FOR SUSPENSION;ORAL - 1GM/PACKET Sponsor INTRABIO Submission history Latest submission status date: 2024-09-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview AQNEURSA is listed in Drugs@FDA under application 219132 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LEVACETYLLEUCINE Form and strength FOR SUSPENSION;ORAL - 1GM/PACKET Sponsor INTRABIO Submission history Latest submission status date: 2024-09-24 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.